Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Another autoimmune CAR-T death; Treasury zeroes in on China deals
26.10.2026 13:59
A patient who received Bristol Myers’ zola-cell died 44 days later. Elswehere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
26.10.2026 13:00
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
26.10.2026 12:15
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach
25.10.2026 12:14
BioNTech (NasdaqGS:BNTX) and Gilead Sciences agreed to a clinical trial collaboration to study pumitamig with sacituzumab govitecan in first-line metastatic triple-negative breast cancer. The partners plan to adapt an existing global Phase 3 trial of pumitamig so that it reflects current clinical standards for treating metastatic triple-negative breast cancer. This will be the first worldwide Phase 3 study to test pumitamig in combination with an antibody-drug conjugate, marking a new step...
Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update
24.10.2026 06:10
Gilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to the depth of its pipeline. Recent news has landed against a strong run in Gilead Sciences’ shares, with the 90 day share price return of 20.67% and year to date gain of 28.32% lifting the stock to US$156.04. The 5 year total shareholder return of 187.39% points to sustained momentum rather than a short...
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
24.10.2026 00:01
Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking.
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
22.10.2026 10:45
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in first-line treatment of metastatic triple-negative breast cancer This will be the first global Phase 3 trial of pumitamig in com
Occidental Petroleum To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Tuesday
20.10.2026 08:52
Analysts cut targets for WING, ELAN, SBAC and RH; raised targets for TRV, OXY and GILD, with ELAN downgraded to Hold.
B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172
20.10.2026 06:53
B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $168 to $172.
How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals
20.10.2026 04:18
Gilead Sciences recently secured multiple FDA decisions, including approval for the Bixlenvo HIV regimen, a label expansion for Trodelvy in first line metastatic triple negative breast cancer, and approval for Hepcludex for chronic hepatitis delta. The company is also preparing to share new data across HIV and antiviral programs at IDWeek 2026. These regulatory milestones arrive as Gilead Sciences absorbs acquired research costs that led to a reported US$3.24b loss over the twelve months to...
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
18.10.2026 17:10
The company's recent momentum continues unabated.
Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?
17.10.2026 11:10
Vir Biotechnology has seen sharp swings over the past few years, which puts fresh focus on a simple question for anyone looking at the stock today: Does the current share price line up with what the business is generating from its sales? Over the last 5 years, the share price has fallen 75.2%, which puts a lot of weight on whether the current valuation still fits the company’s revenue base. The new collaboration with Gilead on dual masked T cell engagers, along with fast track status for...
3 Inflated Stocks Walking a Fine Line
16.10.2026 08:43
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?
15.10.2026 17:17
Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
15.10.2026 14:30
This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
15.10.2026 12:00
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
14.10.2026 13:22
Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead Sciences (GILD)
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
14.10.2026 12:30
SAN FRANCISCO, October 14, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs.
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
14.10.2026 08:40
Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid tumor-associated
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
14.10.2026 08:34
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization